Flotetuzumab is a bispecific antibody targeting CD123 and CD3. It can simultaneously recognize the CD123 antigen on the surface of tumor cells and the CD3 molecule on the surface of effector T cells, thereby activating T cell function and triggering T cell-mediated targeted killing. It shows significant antitumor inhibitory activity in patient-derived xenograft (PDX) mouse models of acute myeloid leukemia (AML).

Flotetuzumab promotes the secretion of IFN‑γ, IL‑10 and IL‑6 when applied to primary peripheral blood mononuclear cells (PBMCs) at concentrations of 0.01 ng/mL and 0.1 ng/mL for 144 h .Within the concentration range of 10⁻⁶ to 10² ng/mL and treatment duration of 24 h, flotetuzumab exerts cytotoxic effects on the acute myeloid leukemia Kasumi‑3 cell line in co-culture systems with human PBMCs or cynomolgus monkey cells [1].

Flotetuzumab exerts antitumor activity in human peripheral blood mononuclear cell (PBMC)-reconstituted tumor-bearing mouse models when administered by intraperitoneal injection and continuous infusion for 6 days at doses of 0.5–4 μg/kg [1].
Flotetuzumab prolongs survival and induces T-cell proliferation in an acute myeloid leukemia (AML) NTPL‑146 patient-derived xenograft (PDX) mouse model when dosed at 0.5 mg/kg every 5 days for 30 days [2].

Human

Monoclonal, Bispecific

Unconjugated